RxDoctor Payments Data

Craig Kuglen, MD

Ophthalmology · Conroe, TXNPI 1639172422

Payments from drug & device makers

$5,655in general payments, 2019–2025

Across 157 payments — averaging $36.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Alcon$782
  • Bausch & Lomb Americas Inc.$524
  • Sun Pharmaceutical Industries Inc.$455
  • Bausch & Lomb, A Division Of Bausch Health US, LLC$358
  • Oyster Point Pharma, Inc.$306
  • plus $1K from 18 others

What the payments were for

  • Food & beverage$5,655100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,655 in reported general payments places this provider in the 75th percentile of 1,355 ophthalmology providers in Texas.

See all ophthalmology providers in Texas

Medicare billing

Part B allowed, 2024
$173,424
Medicare patients
616
Services billed
1,604

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LumiganBimatoprost77$36,736
XiidraLifitegrast25$32,609
RestasisCyclosporine35$30,979
Cyclosporine34$16,925
VyzultaLatanoprostene Bunod22$9,277
Latanoprost607$7,639
Prednisolone Acetate229$6,026
SimbrinzaBrinzolamide/Brimonidine Tart13$4,658
CombiganBrimonidine Tartrate/Timolol17$4,520
MoxifloxacinMoxifloxacin Hcl164$4,036
Brimonidine Tartrate161$3,258
Timolol Maleate188$2,429
Ketorolac Tromethamine163$2,283
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol23$2,226
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha78$848

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan, Restasis, Combigan$1,863$72,235129 claims
Bausch & Lomb Americas Inc.Xiidra, Vyzulta$524$41,88647 claims
AlconSimbrinza$782$4,65813 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,355 ophthalmology providers in Texas.

Other ophthalmology in Conroe

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →